179 related articles for article (PubMed ID: 31337501)
1. Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease.
Sise ME; Chute DF; Oppong Y; Davis MI; Long JD; Silva ST; Rusibamayila N; Jean-Francois D; Raji S; Zhao S; Thadhani R; Chung RT
Kidney Int; 2020 Jan; 97(1):193-201. PubMed ID: 31337501
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.
Sise ME; Backman E; Ortiz GA; Hundemer GL; Ufere NN; Chute DF; Brancale J; Xu D; Wisocky J; Lin MV; Kim AY; Thadhani R; Chung RT
Clin J Am Soc Nephrol; 2017 Oct; 12(10):1615-1623. PubMed ID: 28882857
[TBL] [Abstract][Full Text] [Related]
3. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
[TBL] [Abstract][Full Text] [Related]
4. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series.
Duque JC; Dejman A; Venkat V; Hernandez M; Roth D; Ladino MA
Clin Nephrol; 2021 Jan; 95(1):22-27. PubMed ID: 32909545
[TBL] [Abstract][Full Text] [Related]
5. Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection.
O'Donnell A; Pham N; Battisti L; Epstein R; Nunes D; Sawinski D; Lodi S
PLoS One; 2022; 17(5):e0268478. PubMed ID: 35560032
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C infection and chronic kidney disease among Hispanics/Latinos.
Wong E; Ricardo AC; Rosas SE; Lash JP; Franceschini N
Medicine (Baltimore); 2021 Dec; 100(49):e28089. PubMed ID: 34889260
[TBL] [Abstract][Full Text] [Related]
7. Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update.
Gordon CE; Adam GP; Jadoul M; Martin P; Balk EM
Am J Kidney Dis; 2023 Oct; 82(4):410-418. PubMed ID: 37061019
[TBL] [Abstract][Full Text] [Related]
8. High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents.
Elmowafy AY; El Maghrabi HM; Mashaly ME; Eldahshan KF; Rostaing L; Bakr MA
Int Urol Nephrol; 2019 Dec; 51(12):2243-2254. PubMed ID: 31612423
[TBL] [Abstract][Full Text] [Related]
9. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
[TBL] [Abstract][Full Text] [Related]
10. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD.
Malhotra R; Katz R; Jotwani V; Ambrosius WT; Raphael KL; Haley W; Rastogi A; Cheung AK; Freedman BI; Punzi H; Rocco MV; Ix JH; Shlipak MG
Clin J Am Soc Nephrol; 2020 Mar; 15(3):349-358. PubMed ID: 32111704
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Goel A; Bhadauria DS; Kaul A; Verma P; Mehrotra M; Gupta A; Sharma RK; Rai P; Aggarwal R
Nephrology (Carlton); 2019 Mar; 24(3):316-321. PubMed ID: 29327401
[TBL] [Abstract][Full Text] [Related]
13. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.
D'Ambrosio R; Pasulo L; Giorgini A; Spinetti A; Messina E; Fanetti I; Puoti M; Aghemo A; Viganò P; Vinci M; Menzaghi B; Lombardi A; Pan A; Pigozzi MG; Grossi P; Lazzaroni S; Spinelli O; Invernizzi P; Maggiolo F; Terreni N; Monforte AD; Poggio PD; Taddei MT; Colombo S; Pozzoni P; Molteni C; Brocchieri A; Bhoori S; Buscarini E; Centenaro R; Mendeni M; Colombo AE; Di Marco M; Dionigi E; Bella D; Borghi M; Zuin M; Zaltron S; Noventa F; Annalisa S; Lampertico P; Fagiuoli S
Dig Liver Dis; 2020 Feb; 52(2):190-198. PubMed ID: 31813755
[TBL] [Abstract][Full Text] [Related]
14. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
Said M; Omar H; Soliman Z; Saad Y; Dabes H; Hamed S; ElSaeed K; ElShazly Y; ElSerafy M
Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):89-93. PubMed ID: 30791838
[TBL] [Abstract][Full Text] [Related]
16. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR).
Huang CF; Tseng KC; Cheng PN; Hung CH; Lo CC; Peng CY; Bair MJ; Yeh ML; Chen CH; Lee PL; Lin CY; Kuo HT; Chen CT; Yang CC; Huang JF; Tai CM; Hu JT; Lin CL; Su WW; Tsai WL; Huang YH; Cheng CY; Lin CL; Wang CC; Yang SS; Mo LR; Chen GY; Chang CC; Wang SJ; Huang CS; Hsieh TY; Lin CW; Lee TH; Chong LW; Huang CW; Chang SN; Tsai MC; Hsu SJ; Kao JH; Liu CJ; Liu CH; Lin HC; Lee MH; Tsai PC; Dai CY; Chuang WL; Chen CY; Yu ML
Clin Gastroenterol Hepatol; 2022 May; 20(5):1151-1162.e6. PubMed ID: 34333150
[TBL] [Abstract][Full Text] [Related]
17. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
[TBL] [Abstract][Full Text] [Related]
18. Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience.
Tsai MC; Lin CY; Hung CH; Lu SN; Tung SY; Chien RN; Lin CL; Wang JH; Chien-Hung C; Chang KC; Hu TH; Sheen IS
J Viral Hepat; 2019 Dec; 26(12):1404-1412. PubMed ID: 31433885
[TBL] [Abstract][Full Text] [Related]
19. Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection.
Liu CH; Lin JW; Liu CJ; Su TH; Wu JH; Tseng TC; Chen PJ; Kao JH
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):424-434.e5. PubMed ID: 35131346
[TBL] [Abstract][Full Text] [Related]
20. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
